Cipla USA Inc. (Cipla USA) announced its continued collaboration with the American Lung Association for the 11th annual LUNG FORCE Walk, reaffirming its commitment to advancing respiratory health ...

Cipla Ltd reported a robust 30% YoY increase in consolidated net profit, reaching Rs 1,222 crore for Q4 FY25, driven by strong sales in India, the US, and Africa. For the full fiscal year, net ...

Cipla Q4 Results: Cipla reported a 30.12% year-on-year increase in Q4FY25 net profit, reaching ₹1,221.84 crore, up from ₹939.04 crore. Sales revenue rose by 8.5% YoY to ₹6,597.72 crore ...

Cipla Q4 results: Along with the Q4 results, Cipla announced a final dividend of Rs 13 per equity share for the financial year 2025, and a special dividend of Rs 3 per equity share on the occasion ...

Cipla’s profit after tax (PAT) is estimated at Rs 1,050 crore, a growth of 11.8 per cent YoY, compared to Rs 939 crore in the year-ago quarter. Key business verticals to drive growth US revenues are ...

Cipla Foundation, along with CanSupport, have expanded free palliative home care services in Pune. With nine dedicated home care teams, the initiative will provide supportive care to more than 900 ...

Under this agreement, Cipla has exclusive rights to market the innovative treatment for post-operative inflammation and pain following ocular surgery across 11 countries such as India, South ...

Taiwan-based Formosa Pharmaceuticals (6838.TW) today announced an exclusive licensing agreement with Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as "Cipla" for the commercialization of ...

Vohra expects “Cipla to sustain current earnings or grow them marginally post gRevlimid and doesn’t expect a steep fall.” Nomura pointed out that the comments are “largely aligned with our ...

Afrezza has been approved in the US for more than 10 years and has been prescribed for tens of thousands of patients. MannKind will supply Afrezza to Cipla, who will be then responsible for sales ...

Cipla's consolidated revenue from operations stood at ₹ 7,051.02 crores during the quarter ended September from ₹ 6,678.15 crore in Q2FY24, a year-on-year jump of nearly 10.5%.

Cipla reported a consolidated net profit of 13.03 billion rupees ($155 million) for the quarter ended Sept. 30, beating analysts' estimate of 12.34 billion rupees, as per data compiled by LSEG.